|

Do GLP-1 Drugs Raise the Risk of Sudden Vision Loss? FDA’s 6.4 vs 3.8 per 100,000

ByLife Choice Note

Short answer: On November 9, 2026, the US Food and Drug Administration required all US GLP-1 receptor agonist labels to add a warning about a potential increased risk of nonarteritic anterior ischemic optic neuropathy, or NAION. Across 126 randomized trials, FDA found 6.4 probable NAION events per 100,000 person-years with GLP-1 drugs versus 3.8 with comparators. The event is rare, but sudden painless loss or dimming of vision in one eye needs urgent assessment. The announcement is not a blanket instruction to stop medication on your own.

Announcement date: November 9, 2026 · Region: US FDA labeling · Products: all FDA-approved GLP-1 receptor agonist medications · Evidence reviewed: 126 randomized trials, FDA Sentinel data, postmarketing reports, animal data and observational studies · Reviewed: November 10, 2026

What did FDA change?

FDA is requiring application holders to add the potential NAION risk to the Warnings and Precautions section of US labeling. The action covers FDA-approved products containing agents such as semaglutide, liraglutide, dulaglutide, exenatide and lixisenatide, as well as the dual GIP/GLP-1 agonist tirzepatide and other products listed by FDA.

This is a US regulatory action. It does not automatically change labels in every country on the same date. Patients outside the US need to check their national regulator and the current label for their specific product.

What is NAION?

NAION is a rare optic nerve disorder caused by reduced blood flow to the front of the optic nerve. It commonly presents as sudden, painless decreased vision in one eye and can cause permanent loss. Other symptoms can include a new blind spot or missing portion of vision, tunnel vision, altered color perception, or a blurry or hazy central area.

FDA advises patients to report these symptoms immediately. A previous NAION event raises the risk in the other eye. Other risk factors can include diabetes, high blood pressure, smoking, sleep apnea, anemia and kidney disease—many of which also occur in people prescribed these medicines.

What does 6.4 vs 3.8 per 100,000 mean?

FDA pooled 126 randomized controlled trials involving 134,253 participants: 78,217 received a GLP-1 drug and 56,036 received a comparator. Total exposure was 288,879 person-years. Investigators identified 15 probable NAION events—10 with GLP-1 treatment and five with comparators.

The incidence rates were 6.4 and 3.8 events per 100,000 person-years, an observed absolute difference of 2.6 per 100,000 person-years. A person-year combines the number of people observed and their follow-up time; it is not an exact one-year prediction for an individual. With only 15 events, the analysis cannot precisely separate risk by individual drug, dose or indication.

Did FDA’s real-world study find the same result?

FDA’s retrospective Sentinel cohort compared adults with type 2 diabetes who started a GLP-1 drug, an SGLT2 inhibitor or a DPP-4 inhibitor during 2019–2024. NAION incidence was 30–32 per 100,000 person-years with GLP-1 drugs, 31 with SGLT2 inhibitors and 26 with DPP-4 inhibitors.

The comparison with SGLT2 inhibitors was not statistically significant (HR 1.19; 95% CI, 0.91–1.54). The comparison with DPP-4 inhibitors showed an increase (HR 1.43; 95% CI, 1.02–2.01). The different comparisons illustrate why baseline illness, drug selection and comparator choice matter.

What remains uncertain?

  • FDA describes a potential increased risk; the evidence does not show that every NAION event was caused by a GLP-1 drug.
  • Diabetes, obesity, hypertension and sleep apnea can influence both drug use and NAION risk, leaving possible confounding in observational data.
  • FDA did not identify a biological mechanism in its animal-data review.
  • Only 15 probable events occurred in the randomized-trial analysis, limiting drug-specific conclusions.
  • Spontaneous postmarketing reports cannot by themselves establish incidence or causality because reporting is incomplete and uneven.
  • Absolute risk may differ by age, prior NAION, other eye disease and underlying vascular risk.

What should someone taking a GLP-1 drug do?

Do not stop a GLP-1 medicine solely because of a headline, and do not wait for a routine appointment if sudden visual symptoms occur. Sudden painless loss or dimming of vision in one eye, a new visual-field defect, color distortion or marked new blurring warrants urgent medical assessment.

If NAION is suspected, FDA advises prompt ophthalmology referral. Whether to continue the medicine is an individualized decision that weighs eye risk against diabetes, weight, cardiovascular and kidney benefits. It helps to bring the exact product and dose, start date, timing of symptoms, prior NAION history and relevant conditions such as sleep apnea or diabetic eye disease.

Primary sources checked

By: Life Choice Note · Independent personal health information. This article provides general information and does not diagnose an eye condition or direct an individual to stop or change medication.

Related guides